April 15 (Reuters) - Neumora Therapeutics said on Monday the U.S. Food and Drug Administration had placed a clinical hold on early-stage study of its experimental schizophrenia drug. (Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.925 USD | +0.25% | +4.00% | -41.99% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.99% | 1.58B | |
+49.20% | 54.63B | |
-4.57% | 39.92B | |
+37.18% | 38.82B | |
+16.05% | 26.86B | |
-12.56% | 26.22B | |
-21.89% | 18.78B | |
+25.78% | 12.21B | |
+2.30% | 12.16B | |
+27.03% | 11.94B |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- U.S. FDA places clinical hold on Neumora's schizophrenia drug study